TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick.

The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables. Narrative updates profile some of the candidates that generated the most news over the past year, because they either reported clinical trial results (H56:IC31, BCG revaccination), began major new efficacy trials (M72/AS01E, MTBVAC), prepared to open anticipated studies (QTP101 / ID93/GLA-SE), or kept everyone waiting for more information (VPM1002, MIP).

The world will not end the TB epidemic without new vaccines. Decades of investment in TB research and development are starting to bear fruit with multiple vaccine candidates in late-stage efficacy trials. Although the field has reason for well-earned optimism, progress is tenuous — there are too few novel candidates entering the pipeline, funding for TB vaccine research is growing too slowly, and political upheaval in the United States threatens to upend both scientific progress and public trust in vaccination with consequences for the world. Frick presents promising developments in the pipeline considering these new realities and what they may mean for TB vaccine science.

In case you missed it, in February we released our TB Diagnostics Pipeline Report. And in the coming weeks, TAG will publish the third and final installment of our TB Pipeline Report series on TB treatment.